Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of bimekizumab in adults with moderate-to-severe hidradenitis suppurativa has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: COMPLETED | Results posted: 2025-01-09